image: To register and claim your free ticket, visit the link below: https://2025.bio-hk.com/registration/ Coupon Code: x4rsfuh7
Credit: Insilico Medicine & BIOHK
Artificial Intelligence (AI) is revolutionizing drug discovery by accelerating every stage of the process—from identifying disease mechanisms and designing novel molecules, to draft scientific publications and generating biomedical data. Reflecting this transformative momentum, Roots Analysis projects the global market for AI in pharmaceuticals to reach $13.4 billion by 2035.
As the industry enters the era of AIDD 3.0—which promises deeper AI integration across the entire drug development pipeline, from early discovery and development to clinical management and personalized medicine—Hong Kong stands at the forefront of this transformation. With its strategic location, supportive government policies, and its established role as an international innovation hub and “Super Connector,” Hong Kong is uniquely positioned to lead this global shift.
As a highlight of BIOHK2025—Asia’s premier biotechnology conference and exhibition—Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, will partner with the Hong Kong Biotechnology Association to present a satellite forum themed "Exploring the Frontiers of AI in Drug Discovery, Development, and Beyond", entitled “Towards Pharmaceutical Superintelligence.”
To register and claim your free ticket, visit the link below:
https://2025.bio-hk.com/registration/
Coupon Code: x4rsfuh7
Date: September 10th 13:15 to 16:45
Location: Hong Kong Convention and Exhibition Centre, Suite 3D&3E, Stage1
Distinguished speakers include:
-
Dr. Clara Chan, Chief Executive Officer, Hong Kong Investment Corporation (HKIC)
-
Sir Jonathan Symonds, Chairman, GlaxoSmithKline (GSK)
-
Alex Zhavoronkov, Founder and Chief Executive Officer, Insilico Medicine
-
Feng Ren, Co-CEO and CSO, Insilico Medicine
More speakers to be announced.
BIOHK, the premier biotechnology conference and exhibition in Asia, has witnessed three successful editions, becoming a prominent annual event establishing itself as a premier platform for fostering innovation, collaboration, and investment in the life sciences sector. From pharmaceuticals and health technology to bioinformatics and environmental biotech, past conferences covered the full spectrum of biotech disciplines, bringing together over 200 distinguished speakers from more than 20 countries, and attracting tens of thousands of professionals. BIOHK not only focuses on the development of future technologies, but also strives to build an open and collaborative ecosystem, promote deep integration of scientific research and industry, and accelerate the translation of medical innovations into practice.
At this year's satellite forum, Insilico Medicine will also share its remarkable achievements enabled by the integration of AI and automation technologies. By integrating the technologies of AI and automation, Insilico has demonstrated significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com